Pioneering clinical research carried out at UCL will benefit from almost £12m in new funding, thanks to a major investment by University College London Hospitals NHS Foundation Trust (ULCH).
UCL has a close strategic partnership with UCLH in research, with UCL sponsoring most of the clinical trials held at UCLH and our investigators leading trial evaluation.
The funding will be made available through grants and be used to support research, which will help improve patient outcomes, safety and wellbeing. This includes the development of new and innovative therapies for cancer and dementia, improving digital innovation and maximising use of large-scale health data.
Professor David Lomas, Vice-Provost Health at UCL, said: "This investment is testament to the importance of the partnership between UCLH and the world-leading clinical research carried out at UCL, which is helping transform patient lives."
As part of UCLH's same investment strategy, which totals £20m, the UCLH Charity will also be supported, to help make improvements to patient experience.
The investment in research and patient care will strengthen UCLH's position as a research hospital. It will be spent over the next five years to 2027, and major new infrastructure and projects are as follows.
UCLH Chief Executive David Probert said: "I am delighted we can announce this investment today which will enable improvements in care that our patients will benefit from, and which will enable the development of staff."
Professor Bryan Williams, Director of Research, UCLH, said: "Investment in research like this directly contributes to improvements in clinical care. This is through new and innovative treatments, and indeed, in some cases, the treatments that will be enabled by this investment will be treatments of last resort that have potential to be life-saving or life changing."
